Razelle Kurzrock, MD
Enriched profileCenter Associate Director; Professor of Medicine (Medical Oncology); Linda T. and John A. Mellowes Endowed Chair of Precision Oncology · Medical College of Wisconsin
Razelle Kurzrock is Center Associate Director; Professor of Medicine (Medical Oncology); Linda T. and John A. Mellowes Endowed Chair of Precision Oncology at Medical College of Wisconsin. OpenAlex indexes 2,329 publications with 88,610 citations (h-index 145); ClinicalTrials.gov lists 18 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Razelle Kurzrock, M.D., is Center Associate Director at Medical College of Wisconsin (Froedtert & the Medical College of Wisconsin, Clinical Cancer Center - Froedtert Hospital, Milwaukee, WI). The public record shows 2,329 publications with 88,610 citations (h-index 145), centered on Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 18 registered clinical trials, industry payments reported by 14 companies, 1 NIH-funded awards (2022–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Cancer Genomics and Diagnostics
- 18 registered trials on ClinicalTrials.gov
- Open Payments reporting from 14 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 124 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 892.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 18 registered studies on ClinicalTrials.gov. The most recent:
- Off-Label Treatment With Immune Checkpoint Inhibitor Blockade
Sponsor: Medical College of Wisconsin
- Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence
Sponsor: Medical College of Wisconsin
- MCW Master Predict (Profile Related Evidence Determining Individualized Cancer Therapy)
Sponsor: Sameem M. Abedin, MD
Industry payments
Updated 27 Aug 2026
14 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- ROCHE DIAGNOSTICS INTERNATIONAL LTDProgram year202511 payments$22,801openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim International GmbHProgram year20251 payment
- EMD Serono, Inc.Program year20251 payment
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
- Medical College of Wisconsin Lead Academic Participating Site Renewal
Medical College of Wisconsin
FY2026$651,764UG1CA233198 - MCW NCTN Lead Academic Participating Site Administrative Supplement
Medical College of Wisconsin
FY2025$569,544UG1CA233198
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy.
Molecular cancer therapeutics
Article2026 - Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multicenter Basket Trial Analysis (NCI/SWOG S1609).
Clinical cancer research
Article2026 - GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy.
Molecular cancer therapeutics
Article2026 - Context-Dependent Survival Associations Between Interleukin-13 Expression and Immunotherapy in Advanced Solid Tumors.
ImmunoTargets and therapy
Article2026
Most-cited works
by citation count (OpenAlex)- 01
- 02PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy2,339 citations2015
- 03Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer1,321 citations2008
- 04The Biology of Chronic Myeloid Leukemia1,312 citations1999
- 05The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker1,229 citations2020
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- LinkedIn
linkedin.com/in/razelle-kurzrock-5934757b
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Razelle-Kurzrock
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/Dr_R_Kurzrock
Mentions by others
where others cite or feature them- Instagram
instagram.com/froedtert.mcw/reel/C5E84JTpWE3
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Instagram
instagram.com/p/DOJ6kuNjdfq
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗ - Other
targetcancer.org/team-member/razelle-kurzrock-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →targetcancer.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Board Certified
Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →froedtert.com ↗ - Board Certified
Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →froedtert.com ↗
Editorial & leadership roles
journal and society appointments- Chair
Early Therapeutics and Rare Cancers Committee, SWOG (NCI cooperative group)
- Editorial Board member
CA: A Cancer Journal for Clinicians
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →acsjournals.onlinelibrary.wiley.com ↗ - Equal Opportunity and Diversity Officer
WIN Consortium
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winconsortium.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mcw.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →data.the-asci.org ↗
Secondary affiliations
appointments beyond the home institution- Associate Director of Clinical Research
MCW Cancer Center
- Associate Director of Precision Oncology
Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, MCW
- Founding Director
Michels Rare Cancers Research Laboratories, MCW Cancer Center
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →wtmj.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →targetcancer.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Mary Horowitz, MD
Medical College of Wisconsin
Janet Rader, MD
Medical College of Wisconsin
Bruce Camitta, MD
Medical College of Wisconsin
Thomas Gennarelli, MD
Medical College of Wisconsin